{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:01:24Z","timestamp":1777420884109,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Background: Previous studies show patients with type 2 diabetes (T2D) and a mental health (MH) disorder exhibit poorer glycemic control compared with those without. Objective: Compare mean change in glycosylated hemoglobin (A1C) after 6 months in the Diabetes Intense Medical Management (DIMM) \u201cTune Up\u201d Clinic in patients with and without MH disorders. Methods: Retrospective cohort study in T2D patients, with A1C at baseline and 6 months, divided into subgroups of those with \u22651 MH diagnoses and without MH. Primary outcome was mean change in A1C from baseline to 6 months. Secondary outcomes were mean change in other metabolic parameters and proportion achieving A1C and related goals. Results: Of 155 patients meeting inclusion criteria, 66 (42.6%) had at least 1 MH disorder (MH group) and 89 (57.4%) did not (non-MH group). Mean A1C, fasting blood glucose (FBG), and triglycerides (TG) change (improvement) did not differ significantly between MH and non-MH groups at 6 months (eg, A1C reduction: \u22122.1% [SD = 2.0] vs \u22122.3% [SD = 2.1]; P = 0.61, respectively). Percentage at A1C goal did not differ significantly between groups, though a higher percentage of the non-MH group achieved FBG and TG goals than the MH group. Conclusion and Relevance: In 6 months, both groups in the DIMM clinic achieved a statistically significant mean A1C reduction (over 2%) with no statistical or clinical difference in the magnitude of change between groups. Patients with T2D benefitted from the DIMM model and personalized visits with a pharmacist regardless of having a MH disorder.<\/jats:p>","DOI":"10.1177\/1060028020908856","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T05:12:38Z","timestamp":1582693958000},"page":"858-865","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Improved Glycemic Control Outcomes Regardless of Mental Health Disorders in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) \u201cTune Up\u201d Clinic"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-0234","authenticated-orcid":false,"given":"Candis M.","family":"Morello","sequence":"first","affiliation":[{"name":"UC San Diego, La Jolla, CA, USA"},{"name":"Veterans Affairs of San Diego Healthcare System, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran","family":"Nguyen","sequence":"additional","affiliation":[{"name":"UC San Diego, La Jolla, CA, USA"},{"name":"UC San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Tao","sequence":"additional","affiliation":[{"name":"UC San Diego, La Jolla, CA, USA"},{"name":"MemorialCare Long Beach Medical Center, Long Beach, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan D.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"UC San Diego, La Jolla, CA, USA"},{"name":"Veterans Affairs of San Diego Healthcare System, San Diego, CA, USA"},{"name":"UC Irvine, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"bibr1-1060028020908856","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report, 2017: estimates of diabetes and its burden in the United States. https:\/\/www.cdc.gov\/diabetes\/pdfs\/data\/statistics\/national-diabetes-statistics-report.pdf. Accessed December 21, 2019."},{"key":"bibr2-1060028020908856","unstructured":"National Institute of Mental Health. Mental illness. https:\/\/www.nimh.nih.gov\/health\/statistics\/mental-illness.shtml#part_154785. Accessed December 21, 2019."},{"key":"bibr3-1060028020908856","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302836"},{"key":"bibr4-1060028020908856","doi-asserted-by":"publisher","DOI":"10.5888\/pcd14.1702306"},{"key":"bibr5-1060028020908856","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2018.12.001"},{"key":"bibr6-1060028020908856","first-page":"169","volume-title":"Type 1 Diabetes Sourcebook","author":"Gonzalez JS","year":"2013"},{"key":"bibr7-1060028020908856","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8040"},{"key":"bibr8-1060028020908856","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2016-000198"},{"key":"bibr9-1060028020908856","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2014.08.022"},{"key":"bibr10-1060028020908856","unstructured":"Manigault KR. The bidirectional relationship between depression and diabetes. US Pharm. 2016;41:26-29. https:\/\/www.uspharmacist.com\/article\/the-bidirectional-relationship-between-depression-and-diabetes. Accessed December 11, 2019."},{"key":"bibr11-1060028020908856","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0031"},{"key":"bibr12-1060028020908856","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015615586"},{"key":"bibr13-1060028020908856","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2013.12244"},{"key":"bibr14-1060028020908856","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S012"},{"key":"bibr15-1060028020908856","unstructured":"Department of Veteran Affairs; Department of Defense. VA\/DoD Clinical Practice Guideline for the management of type 2 diabetes mellitus in primary care. https:\/\/www.healthquality.va.gov\/guidelines\/CD\/diabetes\/VADoDDMCPGFinal508.pdf. Accessed February 3, 2020."},{"key":"bibr16-1060028020908856","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2134"},{"key":"bibr17-1060028020908856","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2010.03.011"},{"key":"bibr18-1060028020908856","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-014-0491-3"},{"key":"bibr19-1060028020908856","first-page":"S34","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Standards of Medical Care in Diabetes\u20142019. Diabetes Care"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020908856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020908856","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020908856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:27Z","timestamp":1777374927000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020908856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1177\/1060028020908856"],"URL":"https:\/\/doi.org\/10.1177\/1060028020908856","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]}}}